Proteasome inhibitors and knockdown of SMG1 cause accumulation of Upf1 and Upf2 in human cells

Zhao,Xia; Nogawa,Atsushi; Matsunaga,Tsukasa; Takegami,Tsutomu; Nakagawa,Hideaki; Ishigaki,Yasuhito

doi:10.3892/ijo.2013.2149

Proteasome inhibitors and knockdown of SMG1 cause accumulation of Upf1 and Upf2 in human cells

Authors:
- Xia Zhao
- Atsushi Nogawa
- Tsukasa Matsunaga
- Tsutomu Takegami
- Hideaki Nakagawa
- Yasuhito Ishigaki
View Affiliations

Affiliations: Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.R. China, Laboratory of Human Molecular Genetics, School of Pharmaceutical Sciences, Kanazawa University, Kakuma, Kanazawa 920-1192, Japan, Medical Research Institute, Kanazawa Medical University, Kahoku 920-0293, Japan
Published online on: October 25, 2013 https://doi.org/10.3892/ijo.2013.2149
Pages: 222-228

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The ubiquitin-proteasome system (UPS) is one of the most promising anticancer drug targets of the century. However, the involved molecular mechanisms are still unclear. The nonsense-mediated mRNA decay (NMD) pathway is a highly conserved pathway which degrades nonsense mutation‑containing mRNA selectively and efficiently. In this pathway, the SMG1-Upf1-eRF (SURF) complex binds to Upf2 on the exon junction complex and finally causes degradation of nonsense-containing mRNA. To reveal the relationship between the UPS and NMD pathways, we analyzed the effects of proteasome inhibitors on Upf1 and Upf2. The data showed that treatment with proteasome inhibitors caused the accumulation of the Upf1 and Upf2 proteins in A549 cells. In addition, we found that knockdown of SMG1 also caused the upregulation of Upf1 and Upf2 proteins, which was confirmed by different target sequences of siRNA. SMG1 and UPS appear to participate in different pathways of the degradation of Upf1 and Upf2, since simultaneous treatment with both of them caused additive effects. This study demonstrated the quantitative regulation of Upf1 and Upf2 proteins by UPS and SMG1.

View Figures

View References

1.	Groll M and Potts BC: Proteasome structure, function, and lessons learned from beta-lactone inhibitors. Curr Top Med Chem. 11:2850–2878. 2011. View Article : Google Scholar : PubMed/NCBI
2.	Voges D, Zwickl P and Baumeister W: The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem. 68:1015–1068. 1999. View Article : Google Scholar : PubMed/NCBI
3.	Maquat LE and Carmichael GG: Quality control of mRNA function. Cell. 104:173–176. 2011. View Article : Google Scholar
4.	Neu-Yilik G and Kulozik AE: NMD: multitasking between mRNA surveillance and modulation of gene expression. Adv Genet. 62:185–243. 2008.PubMed/NCBI
5.	Maquat LE: Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat RevMol Cell Biol. 5:89–99. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Czaplinski K, Ruiz-Echevaria MJ, Gonzalez CI and Peltz SW: Should we kill the messenger? The role of the surveillance complex in translation termination and mRNA turnover. Bioessays. 21:685–696. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Yamashita A, Ohnishi T, Kashima I, et al: Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay. Genes Dev. 15:2215–2228. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Kashima I, Yamashita A, Izumi N, et al: Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. Genes Dev. 20:355–367. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Silva AL and Romao L: The mammalian nonsense-mediated mRNA decay pathway: to decay or not to decay! Which players make the decision? FEBS Lett. 583:499–505. 2009.
10.	Lykke-Andersen J, Shu MD and Steitz JA: Human Upf proteins target an mRNA for nonsense-mediated decay when bound downstream of a termination codon. Cell. 103:1121–1131. 2000. View Article : Google Scholar : PubMed/NCBI
11.	Chamieh H, Ballut L and Bonneau F: NMD factors UPF2 and UPF3 bridge UPF1 to the exon junction complex and stimulate its RNA helicase activity. Nat Stuct Mol Biol. 15:85–93. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Danielsen JM, Sylvestersen KB, Bekker-Jensen S, et al: Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site level. Mol Cell Proteomics. 10:M110.0035902011. View Article : Google Scholar : PubMed/NCBI
13.	Ishigaki Y, Nakamura Y, Takehara T, et al: Scanning electron microscopy with an ionic liquid reveals the loss of mitotic protrusions of cells during the epithelial-mesenchymal transition. Microsc Res Tech. 74:1024–1031. 2011. View Article : Google Scholar
14.	Xolalpa W, Perez-Galan P, Rodríguez MS, et al: Targeting the ubiquitin proteasome system: beyond proteasome inhibition. Curr Pharm Des. 19:4053–4093. 2013. View Article : Google Scholar : PubMed/NCBI
15.	Buac D, Shen M, Schmitt S, et al: From Bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des. 19:4025–4038. 2013. View Article : Google Scholar : PubMed/NCBI
16.	Kisselev AF and Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 8:739–758. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 8:2505–2511. 2002.PubMed/NCBI
18.	Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Scagliotti G: Proteasome inhibitors in lung cancer. Crit Rev Oncol Hematol. 58:177–189. 2006. View Article : Google Scholar
20.	Crawford LJ, Walker B and Irvine AE: Proteasome inhibitors in cancer therapy. J Cell Commun Signal. 5:101–110. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Lopes UG, Erhardt P, Yao R, et al: P53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 272:12893–12896. 1997. View Article : Google Scholar : PubMed/NCBI
22.	Pleban E, Bury M, Mlynarczuk I, et al: Effects of proteasome inhibitor PSI on neoplastic and non-transformed cell lines. Folia Histochem Cytobiol. 39:133–134. 2001.PubMed/NCBI
23.	Nakanishi C and Toi M: Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 5:297–309. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Mitsiades N, Mitsiades CS, Poulaki V, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cell. Proc Natl Acad Sci USA. 99:14374–14379. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Russo A, Bronte G, Fulfaro F, et al: Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets. 10:55–67. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Garneau NL, Wilusz J and Wilusz CJ: The highways and byways of mRNA decay. Nat Rev Mol Cell Biol. 8:113–126. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Takahashi S, Araki Y, Ohya Y, et al: Upf1 potentially serves as a RING-related E3 ubiquitin ligase via its association with Upf3 in yeast. RNA. 14:1950–1958. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Kuroha K, Tatematsu T and Inada T: Upf1 stimulates degradation of the product derived from aberrant messenger RNA containing a specific nonsense mutation by the proteasome. EMBO Rep. 10:1265–1271. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Melero R, Buchwald G, Castaño R, et al: The cryo-EM structure of the UPF-EJC complex shows UPF1 poised toward the RNA 3′ end. Nat Struct Mol Biol. 19:498–505. 2012.PubMed/NCBI
30.	Silver DL, Watkins-Chow DE, Schreck KC, et al: The exon junction complex component Magoh controls brain size by regulating neural stem cell division. Nat Neurosci. 13:551–558. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Silver DL, Leeds KE, Hwang HW, et al: The EJC component Magoh regulates proliferation and expansion of neural crest-derived melanocytes. Dev Biol. 375:172–181. 2013. View Article : Google Scholar : PubMed/NCBI
32.	Albers CA, Paul DS, Schulze H, et al: Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet. 44:435–439. 2012. View Article : Google Scholar : PubMed/NCBI
33.	Alachkar A, Jiang D, Harrison M, et al: An EJC factor RBM8a regulates anxiety behaviors. Curr Mol Med. 13:887–899. 2013. View Article : Google Scholar : PubMed/NCBI
34.	Weischenfeldt J, Damgaard I, Bryder D, et al: NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements. Genes Dev. 22:1381–1396. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Long AA, Mahapatra CT, Woodruff EA III, et al: The nonsense-mediated decay pathway maintains synapse architecture and synaptic vesicle cycle efficacy. J Cell Sci. 123:3303–3315. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Thoren LA, Nørgaard GA, Weischenfeldt J, et al: UPF2 is a critical regulator of liver development, function and regeneration. PLoS One. 5:e116502010. View Article : Google Scholar : PubMed/NCBI
37.	Nguyen LS, Kim HG, Rosenfeld JA, et al: Contribution of copy number variants involving nonsense-mediated mRNA decay pathway genes to neuro-developmental disorders. Hum Mol Genet. 22:1816–1825. 2013. View Article : Google Scholar : PubMed/NCBI
38.	Jolly LA, Homan C, Jacob R, et al: The UPF3B Gene, implicated in intellectual disability, autism, ADHD and childhood onset Schizophrenia regulates neural progenitor cell behaviour and neuronal outgrowth. Hum Mol Genet. July 10–2013.(Epub ahead of print).
39.	Nguyen LS, Jolly L, Shoubridge C, et al: Transcriptome profiling of UPF3B/NMD-deficient lymphoblastoid cells from patients with various forms of intellectual disability. Mol Psychiatry. 17:1103–1115. 2012. View Article : Google Scholar : PubMed/NCBI
40.	Szyszka P, Sharp SI, Dedman A, et al: A nonconservative amino acid change in the UPF3B gene in a patient with schizophrenia. Psychiatr Genet. 22:150–151. 2012. View Article : Google Scholar : PubMed/NCBI
41.	Addington AM, Gauthier J, Piton A, et al: A novel frame-shift mutation in UPF3B identified in brothers affected with childhood onset schizophrenia and autism spectrum disorders. Mol Psychiatry. 16:238–239. 2011. View Article : Google Scholar : PubMed/NCBI